HIGHLIGHTS
- who: May-Britt Firnau and Angela Brieger from the Department of Internal Medicine I, Biomedical Research Laboratory, University Hospital Frankfurt, Theodor-Stern-Kai, Frankfurt, Germany have published the article: CK2 and the Hallmarks of Cancer, in the Journal: Biomedicines 2022, 10, 1987. of /2022/
- what: The authors hypothesized that this posttranslational modification might inhibit the ability of MLH1 to interact with MMR process essential proteins or might lead to allosteric conformational changes, inhibiting the endonuclease activity of MutLĪ± , which is the current objective of the research .
SUMMARY
Using the CK2-inhibitor . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.